E Svenungsson

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus
    E Svenungsson
    Department of Medicine, Rheumatology Unit, Karolinska Hospital, S 171 76 Stockholm, Sweden
    Ann Rheum Dis 60:372-9. 2001
  2. ncbi Risk factors for cardiovascular disease in systemic lupus erythematosus
    E Svenungsson
    Department of Rheumatology and Centre for Molecular Medicine, King Gustaf V Research Institute, Karolinska Hospital, Stockholm, Sweden
    Circulation 104:1887-93. 2001
  3. ncbi TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease
    E Svenungsson
    Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
    Lupus 12:454-61. 2003
  4. ncbi Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus
    Elisabet Svenungsson
    Department of Medicine, Karolinska Institute, Stockholm, Sweden
    Arthritis Rheum 48:2533-40. 2003
  5. ncbi Cardiac valvular abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease
    K Jensen-Urstad
    Cardiovascular Laboratory, Department of Medicine, Karolinska Institute at Karolinska Hospital, Stockholm, Sweden
    Lupus 11:744-52. 2002
  6. ncbi No signs of immunoactivation in the cerebrospinal fluid during treatment with infliximab
    M Andersson
    Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
    Ann Rheum Dis 65:1237-40. 2006
  7. ncbi Natural antibodies against phosphorylcholine as potential protective factors in SLE
    J Su
    Rheumatology Unit, Karolinska University Hospital, Huddinge, Karolinska Institutet corrected Stockholm, Sweden
    Rheumatology (Oxford) 47:1144-50. 2008
  8. ncbi Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE-related cardiovascular disease
    X Hua
    Department of Medicine, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden
    Scand J Rheumatol 38:184-9. 2009
  9. ncbi Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus
    L Hopia
    Division of Neurology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden
    Scand J Rheumatol 40:363-72. 2011
  10. ncbi Analysis of JC virus DNA in NPSLE patients treated with different immunomodulatory agents
    E Iacobaeus
    Department of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institute, Sweden
    Lupus 22:307-11. 2013

Collaborators

Detail Information

Publications25

  1. ncbi Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus
    E Svenungsson
    Department of Medicine, Rheumatology Unit, Karolinska Hospital, S 171 76 Stockholm, Sweden
    Ann Rheum Dis 60:372-9. 2001
    ..To investigate systemic and intrathecal production of proinflammatory cytokines in relation to cerebrospinal fluid (CSF) nitric oxide (NO) release in patients with neuropsychiatric lupus erythematosus (NPLE)...
  2. ncbi Risk factors for cardiovascular disease in systemic lupus erythematosus
    E Svenungsson
    Department of Rheumatology and Centre for Molecular Medicine, King Gustaf V Research Institute, Karolinska Hospital, Stockholm, Sweden
    Circulation 104:1887-93. 2001
    ..We determined the prevalence of traditional and nontraditional risk factors for CVD in SLE patients with and without CVD compared with controls...
  3. ncbi TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease
    E Svenungsson
    Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
    Lupus 12:454-61. 2003
    ..sTNFR1 and sTNFR2 are strongly associated with CVD in SLE but their exact roles in disease development remain to be elucidated...
  4. ncbi Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus
    Elisabet Svenungsson
    Department of Medicine, Karolinska Institute, Stockholm, Sweden
    Arthritis Rheum 48:2533-40. 2003
    ....
  5. ncbi Cardiac valvular abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease
    K Jensen-Urstad
    Cardiovascular Laboratory, Department of Medicine, Karolinska Institute at Karolinska Hospital, Stockholm, Sweden
    Lupus 11:744-52. 2002
    ..In conclusion, valvular abnormalities are strongly associated with CVD in SLE. Raised levels of homocysteine and triglycerides characterize patients with cardiac valve abnormalities...
  6. ncbi No signs of immunoactivation in the cerebrospinal fluid during treatment with infliximab
    M Andersson
    Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
    Ann Rheum Dis 65:1237-40. 2006
    ..Induction of systemic IFNgamma production may still be relevant in neuroinflammation associated with treatment with anti-TNFalpha...
  7. ncbi Natural antibodies against phosphorylcholine as potential protective factors in SLE
    J Su
    Rheumatology Unit, Karolinska University Hospital, Huddinge, Karolinska Institutet corrected Stockholm, Sweden
    Rheumatology (Oxford) 47:1144-50. 2008
    ..We have recently reported that natural antibodies against phosphorylcholine (anti-PC) have atheroprotective properties. Here we compare anti-PC with other autoantibodies in SLE patients with and without cardiovascular disease (CVD)...
  8. ncbi Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE-related cardiovascular disease
    X Hua
    Department of Medicine, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden
    Scand J Rheumatol 38:184-9. 2009
    ..This study focused on lipoprotein composition and properties in systemic lupus erythematosus (SLE)...
  9. ncbi Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus
    L Hopia
    Division of Neurology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden
    Scand J Rheumatol 40:363-72. 2011
    ..In particular, the association between fatigue and APRIL/BAFF activity was investigated...
  10. ncbi Analysis of JC virus DNA in NPSLE patients treated with different immunomodulatory agents
    E Iacobaeus
    Department of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institute, Sweden
    Lupus 22:307-11. 2013
    ....
  11. ncbi An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life
    S Pettersson
    Rheumatology Clinic, Karolinska University Hospital, Solna, Stockholm, Sweden
    Scand J Rheumatol 41:383-90. 2012
    ....
  12. ncbi Cutaneous manifestations and serological findings in 260 patients with systemic lupus erythematosus
    C M Grönhagen
    Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Dermatology, Danderyd, Sweden
    Lupus 19:1187-94. 2010
    ..Regular examination by a dermatologist is called for in SLE patients...
  13. ncbi Autoantibodies to the functionally active RING-domain of Ro52/SSA are associated with disease activity in patients with lupus
    M Kvarnstrom
    Department of Medicine, Karolinska Institutet, Sweden
    Lupus 22:477-85. 2013
    ....
  14. ncbi Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus
    Anna Cederholm
    Department of Medicine, Center for Infectious Medicine, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden
    Arterioscler Thromb Vasc Biol 25:198-203. 2005
    ..The cause of the exceedingly high risk of atherothrombosis in systemic lupus erythematosus (SLE) is not clear but antiphospholipid antibodies (aPL) and potentially antithrombotic annexin V have been implicated...
  15. ncbi Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations
    Johan Frostegard
    Center for Infectious Medicine and Center for Metabolism and Endocrinology, Department of Medicine, Karolinska University Hospital, Huddinge, S 141 86 Stockholm, Sweden
    Arthritis Rheum 52:192-200. 2005
    ..Autoantibodies to OxLDL are common in SLE and cross-react with anticardiolipin antibodies (aCL). We therefore hypothesized that lipid peroxidation is enhanced in patients with SLE in general...
  16. ncbi The A-1087IL-10 allele is associated with cardiovascular disease in SLE
    Guo Zhong Fei
    Rheumatology Unit, Department of Medicine at Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden
    Atherosclerosis 177:409-14. 2004
    ..Furthermore, the IL-10 AA genotype is associated with reduced ratio of atheroprotective to atherogenic cytokines in SLE patients with CVD...
  17. ncbi A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans
    Ludmila Prokunina
    Institute of Genetics and Pathology, Section for Medical Genetics, Rudbeck Laboratories, University of Uppsala, Dag Hammarsjölds väg 20, 751 85, Uppsala, Sweden
    Nat Genet 32:666-9. 2002
    ....
  18. ncbi Decreased levels of soluble amyloid beta-protein precursor and beta-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus
    Estelle Trysberg
    Department of Rheumatology and Inflammation Research, Goteborg University, Sahlgrenska University Hospital, Goteborg, Sweden
    Arthritis Res Ther 6:R129-36. 2004
    ..Finally, the increased TGF-beta levels observed may support a notion of an ongoing anti-inflammatory response counteracting tissue injury caused by CNS lupus...
  19. ncbi Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus
    Anna Cederholm
    Karolinska University Hospital, Huddinge, Sweden
    Arthritis Rheum 50:2869-76. 2004
    ..In this cross-sectional study, levels of HSP-related factors, AECA, and sPLA(2) were not associated with CVD in SLE...
  20. ncbi Association of a CD24 gene polymorphism with susceptibility to systemic lupus erythematosus
    Elena Sanchez
    Instituto de Parasitologia y Biomedicina Lopez Neyra, CSIC, Granada, Spain
    Arthritis Rheum 56:3080-6. 2007
    ..To determine the potential role of the CD24 A57V gene polymorphism in systemic lupus erythematosus (SLE)...
  21. ncbi A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5
    Snaevar Sigurdsson
    Molecular Medicine, Department of Medical Sciences, Uppsala University, SE 75185 Uppsala, Sweden
    Hum Mol Genet 17:2868-76. 2008
    ..82-fold risk of SLE with two independent risk alleles of the IRF5 (interferon regulatory factor 5) gene...
  22. ncbi Corrigendum: Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus
    Sergey V Kozyrev
    Nat Genet 40:484. 2008
  23. ncbi Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus
    Sergey V Kozyrev
    Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala 75185, Sweden
    Nat Genet 40:211-6. 2008
    ..The disease-associated variants could contribute to sustained B cell-receptor signaling and B-cell hyperactivity characteristic of this disease...
  24. ncbi Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus
    Snaevar Sigurdsson
    Molecular Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Hum Mol Genet 17:872-81. 2008
    ..We have found that the same IRF5 allele also confers risk for inflammatory bowel diseases and multiple sclerosis, suggesting a general role for IRF5 in autoimmune diseases...
  25. ncbi Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus
    Robert R Graham
    Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA 02142, USA
    Proc Natl Acad Sci U S A 104:6758-63. 2007
    ....